U.S. INTRAVENOUS SOLUTIONS MARKET ANALYSIS

U.S. Intravenous Solutions Market, By Solution Type (Saline(Normal Saline (0.9% NaCl), Hypertonic Solution), Dextran (D5W 5% dextrose in water, Analog Hypertonic Saline), Lactated Ringer’s, Amino Acid, Vitamins & Minerals, Heparin and trace elements, Mixed Solutions), By Packaging (Ampules, Vials, Cartridges, Bottles, Bags (Large Volume Bags (greater than 250ml), Small Volume Bags (less than 250ml)), By Application (Basic IV Solution, Nutritional IV Solution, Blood IV Solution, Drug IV Solution, Irrigation IV Solution), By End User (Hospital, Clinics, Ambulatory Surgical Centers, Home Care Settings, Others)

U.S Intravenous Solutions Market: Key Developments

In June 2022, Breckenridge Pharmaceutical, Inc., a manufacturing company, announced that the U.S. Food and Drug Administration had granted approval of its Abbreviated New Drug Application for cabazitaxel intravenous powder.
In September 2020, Baxter announced that the U.S. Food and Drug Administration (FDA) had approved Clinimix (amino acids in dextrose) injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) injections, which contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.
In September 2021, ICU Medical, Inc., one of the global leaders in IV therapy, announced that it had acquired Smiths Medical, a company developing and manufacturing various medical products used in infusion therapy, vascular access, and vital care applications.